FARESTON Drug Patent Profile
Which patents cover Fareston, and when can generic versions of Fareston launch?
Fareston is a drug marketed by Kyowa Kirin and is included in one NDA.
The generic ingredient in FARESTON is toremifene citrate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the toremifene citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fareston
A generic version of FARESTON was approved as toremifene citrate by RISING on December 4th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FARESTON?
- What are the global sales for FARESTON?
- What is Average Wholesale Price for FARESTON?
Summary for FARESTON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Clinical Trials: | 9 |
| Patent Applications: | 5,536 |
| Drug Prices: | Drug price information for FARESTON |
| What excipients (inactive ingredients) are in FARESTON? | FARESTON excipients list |
| DailyMed Link: | FARESTON at DailyMed |
Recent Clinical Trials for FARESTON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fred Hutchinson Cancer Research Center | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
| Guangdong Provincial People's Hospital | Phase 3 |
Pharmacology for FARESTON
| Drug Class | Estrogen Agonist/Antagonist |
| Mechanism of Action | Selective Estrogen Receptor Modulators |
US Patents and Regulatory Information for FARESTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin | FARESTON | toremifene citrate | TABLET;ORAL | 020497-001 | May 29, 1997 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FARESTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Kyowa Kirin | FARESTON | toremifene citrate | TABLET;ORAL | 020497-001 | May 29, 1997 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FARESTON
See the table below for patents covering FARESTON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 22064 | ⤷ Start Trial | |
| Austria | 383344 | ⤷ Start Trial | |
| Austria | A192983 | ⤷ Start Trial | |
| Australia | 1494683 | ⤷ Start Trial | |
| Australia | 556608 | ⤷ Start Trial | |
| Bulgaria | 60760 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FARESTON
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0095875 | SPC/GB96/029 | United Kingdom | ⤷ Start Trial | |
| 0095875 | 96C0029 | Belgium | ⤷ Start Trial | PRODUCT NAME: TOREMIFENE; REGISTRATION NO/DATE: EU/1/96/004/001 19960215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch